A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma.

Published

Journal Article

Both the amplification of the gene coding for wild-type (wt) epidermal growth factor receptor (EGFR) and the overexpression of the EGFR deletion mutant, commonly known as EGFRvIII, are hallmarks of glioblastoma. We have recently reported a novel, recombinant immunotoxin, D2C7-(scdsFv)-PE38KDEL, that targets both wt EGFR and EGFRvIII, exhibiting potent antineoplastic effects against established murine gliomas.

Full Text

Duke Authors

Cited Authors

  • Chandramohan, V; Bigner, DD

Published Date

  • December 1, 2013

Published In

Volume / Issue

  • 2 / 12

Start / End Page

  • e26852 -

PubMed ID

  • 24498557

Pubmed Central ID

  • 24498557

International Standard Serial Number (ISSN)

  • 2162-4011

Digital Object Identifier (DOI)

  • 10.4161/onci.26852

Language

  • eng

Conference Location

  • United States